BRAF and neoplasm: Targeting of other altered oncogenes (e.g., B-Raf proto-oncogene—BRAF, ROS proto-oncogene 1—ROS1, anaplastic lymphoma kinase—ALK, fibroblast growth factor receptors—FGFR, neurotrophic tyrosine receptor kinase—NTRK, Kirsten rat sarcoma virus–KRAS) showed efficiency [5], giving rise to the concept of precision medicine, which aims at treating patients according to the molecular portrait of their tumor.